In a blockbuster deal announced on February 17, 2026, industrial conglomerate Danaher Corp has agreed to acquire medical technology firm Masimo Corp for $9.9 billion, including debt.

͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­͏     ­

	Forwarded this email? Subscribe here for more Danaher to acquire pulse oximeter maker Masimo in $9.9 billion deal; could help Apple in ongoing patent battles MacDailyNews Feb 17   READ IN APP   In a blockbuster deal announced on February 17, 2026, industrial conglomerate Danaher Corp has agreed to acquire medical technology firm Masimo Corp for $9.9 billion, including debt. The transaction, which values Masimo at $180 per share — a hefty 38.3% premium over its recent closing price — could have far-reaching implications beyond the diagnostics sector, particularly for Apple, which has been locked in a protracted legal feud with Masimo over pulse oximetry patents. Masimo, known for its innovative pulse oximeters that measure blood oxygen levels non-invasively, has been a thorn in Apple’s side since 2020. The Irvine, California-based company accused Apple of infringing on its patents related to health monitoring technology integrated into the Apple Watch. This dispute escalated to the U.S. International Trade Commission (ITC), which in late 2023 ruled in Masimo’s favor, leading to a temporary import ban on certain Apple Watch models equipped with blood oxygen sensors. Apple was forced to disable the feature in new U.S. sales to comply, while appealing the decision and exploring workarounds. The legal wrangling has cost Apple millions in legal fees and disrupted its wearable strategy, with ongoing appeals and countersuits adding uncertainty to one of its fastest-growing product lines. Enter Danaher, a Washington, D.C.-based powerhouse with a market cap exceeding $150 billion, far dwarfing Masimo’s roughly $7 billion valuation. Danaher, which specializes in life sciences, diagnostics, and environmental technologies, views the acquisition as a strategic bolt-on to bolster its diagnostics portfolio amid broader industry headwinds like U.S. drug pricing reforms and potential tariffs. By absorbing Masimo, Danaher gains access to cutting-edge sensor technologies that could integrate with its existing tools for hospital and clinical settings. For Apple, this shift in Masimo’s ownership could prove transformative. Under Danaher’s umbrella, Masimo’s aggressive litigation stance might soften. Large conglomerates like Danaher often prioritize cross-industry partnerships and licensing deals over prolonged courtroom battles, especially when they involve non-core consumer tech applications. Analysts speculate that Danaher could negotiate a settlement or licensing agreement with Apple, allowing the Cupertino company to reinstate the blood oxygen feature without further infringement claims. This would not only resolve the ITC ban but also free up Apple’s resources to innovate in health tech, a key differentiator for the Apple Watch against competitors like Samsung and Fitbit. Moreover, Danaher’s scale and diversified operations — spanning from water purification to biotech — might de-emphasize Masimo’s consumer-facing patent enforcement, focusing instead on enterprise healthcare solutions. If the deal closes as expected later in 2026, pending regulatory approvals, it could mark the end of an era of hostility, paving the way for collaborative advancements in wearable health monitoring. While the acquisition’s primary driver is Danaher’s growth ambitions, its ripple effects on Apple’s legal landscape underscore how mergers in medtech can reshape tech rivalries. Apple shares ticked up slightly in early trading following the news, reflecting investor optimism about a potential detente. As the deal progresses, all eyes will be on whether this $9.9 billion move finally pulses new life into Apple’s smartwatch ambitions. ‎ MacDailyNews Take: Could be great news for Apple and Apple Watch owners who use its blood oxygen monitoring capability! ‎ Please help support MacDailyNews — and enjoy subscriber-only articles, comments, chat, and more — by subscribing to our Substack: macdailynews.substack.com. Thank you! Support MacDailyNews at no extra cost to you by using this link to shop at Amazon. The post Danaher to acquire pulse oximeter maker Masimo in $9.9 billion deal; could help Apple in ongoing patent battles appeared first on MacDailyNews. You're currently a free subscriber to MacDailyNews. For the full experience, upgrade your subscription. Upgrade to paid   Like Comment Restack   © 2026 MacDailyNews 548 Market Street PMB 72296, San Francisco, CA 94104 Unsubscribe